-
Ab182875-5mgGiloralimab (anti-CD40) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab (anti-CD40) has the potential for the research of cancer.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab182875-1mgGiloralimab (anti-CD40) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab (anti-CD40) has the potential for the research of cancer.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab182875-10mgGiloralimab (anti-CD40) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab (anti-CD40) has the potential for the research of cancer.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab182875-100μgGiloralimab (anti-CD40) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab (anti-CD40) has the potential for the research of cancer.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab182865-5mgVixarelimab (anti-OSMR) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab (anti-OSMR) can be used in studies of inflammatory skin diseases such
-
Ab182865-1mgVixarelimab (anti-OSMR) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab (anti-OSMR) can be used in studies of inflammatory skin diseases such
-
Ab182865-10mgVixarelimab (anti-OSMR) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab (anti-OSMR) can be used in studies of inflammatory skin diseases such
-
Ab182865-100μgVixarelimab (anti-OSMR) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab (anti-OSMR) can be used in studies of inflammatory skin diseases such
-
Ab182860-5mgRavagalimab (anti-CD40) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab (anti-CD40) can be used for research of Crohn's disease.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab182860-1mgRavagalimab (anti-CD40) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab (anti-CD40) can be used for research of Crohn's disease.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab182860-10mgRavagalimab (anti-CD40) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab (anti-CD40) can be used for research of Crohn's disease.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab182860-100μgRavagalimab (anti-CD40) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab (anti-CD40) can be used for research of Crohn's disease.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.